Last filing: May 6, 2026.
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 0 of the 13 calendar months from Oct 2025 to Oct 2026.
- No sale on record before this period.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| Incyte (INCY) | EVP & Chief Financial Officer | May 6, 2026 | May 6, 2026 |
| Vertex Pharmaceuticals (VRTX) | Director | May 19, 2022 | May 5, 2026 |
| Zimmer Biomet (ZBH) | Exec VP, CFO | Jul 3, 2019 | Mar 10, 2026 |
| Becton Dickinson (BDX) | Former Senior VP and Controller | Dec 2, 2011 | Nov 21, 2012 |
Also a director at
Recent filings
The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- May 4, 2026, Incyte: 26,343 shares granted. 1 filing: 1
- May 1, 2026, Vertex Pharmaceuticals: 796 shares returned to the company. 1 filing: 1
- Mar 6, 2026, Zimmer Biomet: 14,776 shares vested; 6,576 shares withheld by the company for taxes. 1 filing: 1
- Feb 25, 2026, Zimmer Biomet: 6,364 shares vested; 2,832 shares withheld by the company for taxes. 1 filing: 1
- Feb 20, 2026, Zimmer Biomet: 5,445 shares vested; 2,446 shares withheld by the company for taxes. 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.